Peptide Therapy

Tirzepatide

Tirzepatide is a dual GIP and GLP-1 receptor agonist that helps regulate appetite, metabolism, and blood sugar control. By targeting two complementary hormone pathways involved in hunger and satiety, tirzepatide often produces greater weight loss and appetite suppression than GLP-1 therapy alone.

Originally FDA approved as Mounjaro® and Zepbound®, tirzepatide has quickly become one of the most effective medications available for medical weight loss and metabolic optimization. It is commonly prescribed through licensed pharmacies as part of a provider-supervised treatment plan.

• Powerful appetite suppression and craving reduction
• Supports significant weight loss and fat reduction
• Improves blood sugar control and insulin sensitivity
• Increases satiety and reduces overeating
• Helps preserve lean muscle mass during weight loss when combined with adequate protein intake and exercise
• Supports long-term metabolic health and weight maintenance

Semaglutide

Semaglutide is a GLP-1 receptor agonist that helps regulate appetite, food intake, and blood sugar levels. By mimicking a naturally occurring hormone released after eating, semaglutide helps patients feel fuller for longer, reduce cravings, and consume fewer calories throughout the day.

Originally FDA approved as Ozempic® and Wegovy®, semaglutide has become one of the most widely prescribed medications for medical weight loss and metabolic health. It is commonly prescribed through licensed pharmacies as part of a provider-supervised weight management program.

• Reduces appetite and food cravings
• Promotes sustainable weight loss
• Improves blood sugar regulation and insulin sensitivity
• Increases feelings of fullness after meals
• Supports long-term weight maintenance
• May improve cardiovascular and metabolic health

Tesamorelin

Tesamorelin is a growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary gland to increase the body's natural production and release of growth hormone. Unlike exogenous HGH, tesamorelin works through the body's normal hormonal pathways, supporting physiologic growth hormone secretion while preserving natural feedback mechanisms.

Originally FDA approved as Egrifta®, tesamorelin has been extensively studied for its effects on body composition, visceral fat reduction, recovery, and metabolic health. It is now commonly prescribed through licensed compounding pharmacies as part of provider-supervised wellness and hormone optimization programs.

• Stimulates natural growth hormone and IGF-1 production
• Supports reduction of stubborn abdominal and visceral fat
• Promotes lean muscle mass and improved body composition
• Enhances recovery, energy, and physical performance
• May improve metabolic health and insulin sensitivity
• Preserves pituitary axis feedback unlike exogenous HGH

Sermorelin

Sermorelin (GHRH 1–29) is one of the most established peptides used in provider supervised hormone optimization. It stimulates the pituitary gland to produce and release growth hormone naturally, preserving the body's own feedback mechanisms rather than bypassing them with synthetic HGH.

Originally FDA approved as Geref (sermorelin acetate), sermorelin is now commonly prescribed as a licensed compounded medication through 503A and 503B pharmacies.

• Stimulates natural, pulsatile growth hormone release
• Supports lean body composition and fat metabolism
• Improves sleep quality and overnight recovery
• Enhances energy, stamina, and mental clarity
• Preserves pituitary axis feedback unlike exogenous HGH

PT-141

PT-141 (bremelanotide) is the active ingredient found in Vyleesi, an FDA approved medication for hypoactive sexual desire disorder (HSDD). Unlike traditional erectile dysfunction medications that work by increasing blood flow, PT-141 acts on melanocortin receptors in the brain to enhance sexual desire and arousal at a neurological level.

PT-141 is FDA approved as Vyleesi for premenopausal women with HSDD and is commonly prescribed off label for men under physician supervision when sexual dysfunction or low libido persists despite hormonal optimization.

• Contains the FDA approved active ingredient found in Vyleesi
• Supports increased sexual desire and arousal through central nervous system pathways
• May complement testosterone replacement therapy in patients with persistent low libido
• Nonvascular mechanism of action for patients who may not be candidates for PDE5 inhibitors
• Administered as a subcutaneous injection prior to anticipated sexual activity

Looking for something specific?

The peptide landscape is continuously evolving. During your consultation, our providers can discuss the full range of clinically evaluated options that may be appropriate for your individual health goals, including therapies not listed here.

All recommendations are based on your health goals, lab results, medical history, symptoms, and current regulatory guidelines.